SEC Form 4 · accession 0001179110-18-014132
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip S Low
Officer — Chief Science Officer · Director
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 12, 2018 | G | 52,512 | $0.00 | D | 132,473 | I | By Spouse Trust |
| Common StockF2 | Dec 12, 2018 | G | 52,346 | $0.00 | D | 269,204 | D | |
| Common StockF3 | Dec 17, 2018 | M | 22,759 | $2.54 | A | 292,489 | D | |
| Common Stock | Dec 17, 2018 | M | 51,875 | $3.82 | A | 344,364 | D | |
| Common Stock | Dec 17, 2018 | M | 21,440 | $9.05 | A | 365,804 | D | |
| Common Stock | Dec 17, 2018 | M | 2,050 | $11.80 | A | 367,854 | D | |
| Common Stock | Dec 17, 2018 | M | 20,004 | $3.55 | A | 387,858 | D | |
| Common Stock | Dec 17, 2018 | M | 13,082 | $9.86 | A | 400,940 | D | |
| Common Stock | Dec 17, 2018 | M | 9,000 | $11.11 | A | 409,940 | D | |
| Common Stock | Dec 17, 2018 | M | 2 | $5.10 | A | 409,942 | D | |
| Common Stock | Dec 17, 2018 | M | 2 | $3.18 | A | 409,944 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $2.54 | Dec 17, 2018 | M | 22,759 | D | — | Mar 5, 2019 | Common Stock | 22,759 | 0 | D |
| Stock Option (right to buy)F4 | $3.82 | Dec 17, 2018 | M | 51,875 | D | — | Feb 11, 2020 | Common Stock | 51,875 | 13,570 | D |
| Stock Option (right to buy)F4 | $9.05 | Dec 17, 2018 | M | 21,440 | D | — | Apr 14, 2021 | Common Stock | 21,440 | 8,560 | D |
| Stock option (right to buy)F4 | $11.80 | Dec 17, 2018 | M | 2,050 | D | — | May 26, 2021 | Common Stock | 2,050 | 17,950 | D |
| Stock option (right to buy)F4 | $3.55 | Dec 17, 2018 | M | 20,004 | D | — | Feb 28, 2022 | Common Stock | 20,004 | 59,996 | D |
| Stock option (right to buy)F4 | $9.86 | Dec 17, 2018 | M | 13,082 | D | — | Feb 19, 2023 | Common Stock | 13,082 | 56,918 | D |
| Stock option (right to buy)F4 | $11.11 | Dec 17, 2018 | M | 9,000 | D | — | Feb 6, 2024 | Common Stock | 9,000 | 36,000 | D |
| Stock option (right to buy)F4 | $5.10 | Dec 17, 2018 | M | 2 | D | — | Feb 4, 2025 | Common Stock | 2 | 52,498 | D |
| Stock option (right to buy)F5 | $3.18 | Dec 17, 2018 | M | 2 | D | — | Feb 4, 2026 | Common Stock | 2 | 52,498 | D |
Explanation of responses
- F1Represents gifts of 52,512 shares by Spouse Trust to non-profit organizations.
- F2Represents a gift of 52,346 shares to a non-profit organization.
- F3Includes 526 shares acquired under the 2010 Endocyte, Inc. Employee Stock Purchase Plan on December 14, 2018.
- F4The option is fully vested and immediately exercisable.
- F5Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017.